So far, patients with ET have been stratified by various models for vascular complications’ risk (mainly thrombotic) using factors like age (<40, 40–59 and 60 years), history of thrombosis, and JAK2/MPL/CALR mutation status and assessed for cardiovascular risk factors including hypertension, diabetes, and others. The gene discussed is JAK2; the disease is deep vein thrombosis.